NYC’s top research institutions partner on Step 2 in building a biotech hub
A trio of New York’s best known research institutions have allied with Takeda and a pair of biotech investors to start up a new company that will carry some promising new programs into clinical development.
Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine partnered with the restructuring Takeda along with Bay City Capital and Deerfield Management to create Bridge Medicines.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.